The strong correlation between cancer treatment delay, reduced survival
, and higher healthcare cost
has focused national attention on the importance of timely treatment of cancer. As a result, prompt “time to treatment” has been adopted as a quality measure by several national professional societies
, advocacy groups
, and accreditation organizations
. Time to treatment is on the verge of being regulated by emerging federal
legislation. Payers are already being penalized
for delaying life-saving care. Ironically, new “time to treatment” standards are being established despite the absence of proven, evidence-based solutions to ensure timely care delivery.
Enter XpediteMD as a care delivery solution for a new generation. Created by physicians, researchers, and utilization management experts, XpediteMD is an evidence-based, clinical management and prior authorization solution that conveniently slots into clinical workflows and accomplishes what other solutions only aspire to do: reliably increase the efficiency, quality, and value of cancer care.
By combining clinical decision support, novel patient and order tracker mechanisms, and automated prior authorization, the XpediteMD eliminates the gap between patient care decisions and approval of guideline-compliant care while also minimizing delays between the initiation, scheduling, completion, and resolution of medical orders. The end result is improved efficiency, value, and equity of cancer care while enhancing patient, provider, and payor experience.